These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36658575)

  • 1. Tenofovir-tethered gold nanoparticles as a novel multifunctional long-acting anti-HIV therapy to overcome deficient drug delivery-: an in vivo proof of concept.
    Fotooh Abadi L; Kumar P; Paknikar K; Gajbhiye V; Kulkarni S
    J Nanobiotechnology; 2023 Jan; 21(1):19. PubMed ID: 36658575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nevirapine Loaded Core Shell Gold Nanoparticles by Double Emulsion Solvent Evaporation: In vitro and In vivo Evaluation.
    Dalvi BR; Siddiqui EA; Syed AS; Velhal SM; Ahmad A; Bandivdekar AB; Devarajan PV
    Curr Drug Deliv; 2016; 13(7):1071-1083. PubMed ID: 26777885
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Yadavar-Nikravesh MS; Milani A; Vahabpour R; Khoobi M; Bakhshandeh H; Bolhassani A
    Curr HIV Res; 2021; 19(2):138-146. PubMed ID: 33045968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene Phosphoric Acid) Block Copolymers Increase the Efficiency of Tenofovir against HIV-1 in MT-4 Cells.
    Nifant'ev I; Siniavin A; Karamov E; Kosarev M; Kovalchuk S; Turgiev A; Nametkin S; Bagrov V; Tavtorkin A; Ivchenko P
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
    Perazzolo S; Shireman LM; Koehn J; McConnachie LA; Kraft JC; Shen DD; Ho RJY
    J Pharm Sci; 2018 Dec; 107(12):3153-3162. PubMed ID: 30121315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
    Ma J; Nance RM; Delaney JAC; Whitney BM; Bamford L; Gravett RM; Moore RD; Napravnik S; Mayer KH; Jacobson JM; Christopoulos K; Burkholder GA; Keruly J; Eron JJ; Martin J; Cachay ER; Saag MS; Crane HM; Kitahata MM
    Clin Infect Dis; 2022 Sep; 75(4):715-718. PubMed ID: 35134850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-organ targeting of HIV-1 viral reservoirs with etravirine loaded nanostructured lipid carrier: An in-vivo proof of concept.
    Rojekar S; Fotooh Abadi L; Pai R; Mahajan K; Kulkarni S; Vavia PR
    Eur J Pharm Sci; 2021 Sep; 164():105916. PubMed ID: 34166780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Contributing to the Antiviral Effectiveness of Tenofovir.
    Murphy RA; Valentovic MA
    J Pharmacol Exp Ther; 2017 Nov; 363(2):156-163. PubMed ID: 28860352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting slow effective release antiretroviral therapy.
    Edagwa B; McMillan J; Sillman B; Gendelman HE
    Expert Opin Drug Deliv; 2017 Nov; 14(11):1281-1291. PubMed ID: 28128004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice.
    Weichseldorfer M; Affram Y; Heredia A; Rikhtegaran-Tehrani Z; Sajadi MM; Williams SP; Tagaya Y; Benedetti F; Ramadhani HO; Denaro F; Munawwar A; Bryant J; Zella D; Reitz M; Romerio F; Latinovic OS
    J Transl Med; 2021 Oct; 19(1):453. PubMed ID: 34717655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.
    Gao Y; Kraft JC; Yu D; Ho RJY
    Eur J Pharm Biopharm; 2019 May; 138():75-91. PubMed ID: 29678735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.
    Shao J; Kraft JC; Li B; Yu J; Freeling J; Koehn J; Ho RJ
    Nanomedicine (Lond); 2016; 11(5):545-64. PubMed ID: 26892323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB; Stone EA; Piacenti FJ
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro.
    Huang XS; Luo RH; Hu XL; Chen H; Xiang SY; Tang CR; Zhang CT; Shen XN; Zheng YT
    Curr HIV Res; 2020; 18(5):332-341. PubMed ID: 32562524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low-income and middle-income countries.
    Inzaule SC; Jordan MR; Cournil A; Girón-Callejas A; Avila-Rios S; Mulenga L; Ssemwanga D; Asio J; Diop-Ndiaye H; Niasse-Traore F; Nhan DT; Dat VQ; Aghokeng AF; Billong S; Cham F; Doherty M; Bertagnolio S;
    AIDS; 2020 Nov; 34(13):1965-1969. PubMed ID: 32694410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
    Imaz A; Podzamczer D
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients.
    Montejano R; Stella-Ascariz N; Monge S; Bernardino JI; Pérez-Valero I; Montes ML; Valencia E; Martín-Carbonero L; Moreno V; González-García J; Arnalich F; Mingorance J; Pintado Berniches L; Perona R; Arribas JR
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):102-109. PubMed ID: 28418989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systems Approach to targeted and long-acting HIV/AIDS therapy.
    Ho RJ; Yu J; Li B; Kraft JC; Freeling JP; Koehn J; Shao J
    Drug Deliv Transl Res; 2015 Dec; 5(6):531-9. PubMed ID: 26315144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-treatment and acquired HIV drug resistance in Dar es Salaam, Tanzania in the era of tenofovir and routine viral load monitoring.
    Barabona G; Mahiti M; Masoud S; Mbelele P; Mgunya AS; Minja L; Sunguya B; Shigemi U; Matsuda M; Hachiya A; Iwatani Y; Lyamuya E; Ueno T
    J Antimicrob Chemother; 2019 Oct; 74(10):3016-3020. PubMed ID: 31273377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.
    Maeda K; Das D; Kobayakawa T; Tamamura H; Takeuchi H
    Curr Top Med Chem; 2019; 19(18):1621-1649. PubMed ID: 31424371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.